In the IBIS-I randomised controlled trial , premenopausal and postmenopausal women 35-70 years of age deemed to be at an increased risk of developing breast cancer were randomly assigned ( 1:1 ) to receive oral tamoxifen 20 mg daily or matching placebo for 5 years .